[Pseudotumorous presentation of neuro-Behçet: role of the withdrawal of colchicine?].
BACKGROUND
Neurological involvement occurs in 10 to 28% of patients with Behçet's disease.


METHODS
We report a case of neurological pseudotumoral presentation of Behçet's in a patient with a long standing disease treated with low dose of prednisone and colchicine (1 mg/day), 2 months after withdrawal of colchicine.


CONCLUSIONS
Neurological manifestations during Behçet disease can be secondary to direct central nervous system involvement (encephalitis, encephalomyelitis) or vascular angitis (essentially cerebral venous thrombosis and, rarely, intracranial aneurysms). Neurological pseudotumoral presentation is rarely reported.
Vignes
S
S
Service de médecine interne, hôpital de la Pitié-Salpétrière, Paris.
Vidailhet
M
M
Dormont
D
D
Soulié
J
J
Wechsler
B
B
D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001528:Behcet Syndrome / Q000175:diagnosis* / Q000188:drug therapy; D001927:Brain Diseases / Q000139:chemically induced* / Q000175:diagnosis; D003078:Colchicine / Q000008:administration & dosage / Q000009:adverse effects*; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006074:Gout Suppressants / Q000009:adverse effects*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage / Q000627:therapeutic use; D013375:Substance Withdrawal Syndrome; D013997:Time Factors
D000893:Anti-Inflammatory Agents; D006074:Gout Suppressants; D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D003078:Colchicine; D011241:Prednisone
Présentation pseudotumorale de neuro-Behçet: rôle de l'arrêt de la colchicine?